Exact Sciences spikes ahead of data for blood-based cancer test
Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance ...
STAT3d
Biotech feud over the multibillion-dollar cancer blood test market spills onto social media
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
Business Wire6d
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
“The Exact Sciences team is constantly innovating to help close the screening gap,” said Kevin Conroy, chairman and CEO, Exact Sciences. “The insights that led to this innovation reflect our ...
FierceBiotech5d
ESMO: Exact Sciences shows off early colorectal cancer blood test data
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...
The battle brewing over blood tests for cancer
Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...